Please find below a list of our press releases.

14 Oct 2016

BTG and Mirada Medical announce CE Mark Certification for Simplicit Y90 dosimetry software in Europe

New easy-to-use software designed to improve the planning of Y90 selective internal radiation therapy (SIRT) treatment for patients with liver cancer

BTG plc (LSE: BTG), an international specialist healthcare company, with Mirada Medical Ltd, a leading global brand in medical imaging software, today announced CE Mark certification for Simplicit Y90™ dosimetry software, designed to optimise the planning of Y90 selective internal radiation therapy (SIRT) and facilitate personalised treatment for patients with liver cancer. CE Mark certification follows approval for Simplicit Y90™ in Canada.

15 Jun 2016

BTG completes the acquisition of Galil Medical

BTG completes the acquisition of Galil Medical

9 Jun 2016

BTG Joins Global Liver Institute Partnership Network to Transform Care for Liver Cancer Patients

BTG, a global leader in interventional oncology, announced today that it has joined the Global Liver Institute’s Partnership Network as a founding member.

26 May 2016

New study highlights potential cost savings using Y90 glass microspheres in hcc

New study highlights potential cost savings when using yttrium-90 glass microspheres for treatment of hepatocellular carcinoma

6 May 2016

BTG plc acquires Galil Medical, a leader in cryoablation

Builds on BTG’s leadership in Interventional Oncology, expanding franchise into attractive and complementary ablation market

5 Apr 2016

Patients with colorectal liver metastases gain wider access to unique benefits of yttrium-90 internal radiation therapy in the Netherlands

Selective internal radiation therapy (SIRT), including TheraSphere®, reimbursed by Zorginstituut Nederland

2 Apr 2016

BTG to initiate multi-centre TARGET study

BTG plc (LSE: BTG), a global specialist healthcare company, today announced plans to initiate the TheraSphere® Advanced Dosimetry Retrospective Global Study Evaluation in Hepatocellular Carcinoma Treatment (TARGET).

1 Apr 2016

BTG announces US launch of LC Bead LUMI™

First and only, commercially available, radiopaque embolic bead in the US has potential to revolutionize treatment of hypervascular tumors and arteriovenous malformations

10 Mar 2016

BTG International Canada Expands Operations To Directly Sell Interventional Oncology Products

DC Bead®, DC BeadM1® and Bead Block® Now Sold Directly to Specialist Physicians Across Canada